Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.

ABSTRACT:

Background

Metastatic urothelial carcinoma (mUC) is a genomically diverse disease with known alterations in the mTOR pathway and tyrosine kinases including FGFR. We investigated the efficacy and safety of combination treatment with everolimus and pazopanib (E/P) in genomically profiled patients with mUC.

Methods

mUC patients enrolled on a Phase I dose escalation study and an expansion cohort treated with E/P were included. The primary end point was objective response rate (ORR); secondary end points were safety, duration of response (DOR), progression-free survival (PFS) and overall survival (OS). Patients were assessed for mutations and copy number alterations in 300 relevant cancer-associated genes using next-generation sequencing and findings were correlated with outcomes

SUBMITTER: Bellmunt J 

PROVIDER: S-EPMC6173710 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature